Trial Profile
An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma (EXCELS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 May 2017
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Acronyms EXCELS
- Sponsors Genentech
- 14 Sep 2016 Results assessing association between omalizumab and cardiovascular and cerebrovascular events in EXCELS, published in the Journal of Allergy and Clinical Immunology.
- 12 Jul 2016 New trial record